Plus   Neg

Busy Year Ahead For OMED, There's HOPE For GBT, APLS Sinks Below IPO Price


The following are some of the stocks that lost the largest percentage in price today in the pharma/biotech sector.

1. OncoMed Pharmaceuticals Inc. (OMED)

Lost 15.52% to close Tuesday's (Dec.12) trading at $3.92.

News: No news

Clinical trials & Near-term catalysts:

-- A phase Ia single agent study of GITRL-Fc in patients with advanced or metastatic solid tumors is ongoing.
-- Two phase Ib trials of Navicixizumab in combination with standard of care chemotherapies - one in patients with 2nd line metastatic colorectal cancer and a second in patients with platinum-resistant ovarian cancer are underway.
-- A phase 1a/b study of Rosmantuzumab in advanced solid tumors (Phase 1a) and in patients with previously treated metastatic colorectal or gastric cancer (Phase 1b) is ongoing. Interim data are expected to be reported in 2018.
-- A Phase 1a study of anti-TIGIT antibody in patients with advanced or metastatic solid tumors is underway. Interim data is expected to be reported by year-end 2018.
-- The phase 1b portion of its anti-TIGIT trial to study anti-TIGIT in combination with anti-PD1 is expected to be initiated in the first half of 2018.

2. Global Blood Therapeutics Inc. (GBT)

Lost 14.24% to close Tuesday's trading at $38.40.

News: The data from a case study of seven patients with severe sickle cell disease who were treated with once-daily oral investigational therapy, Voxelotor under a compassionate program reveled that 2 patients died while receiving Voxelotor.

However, the patients treated with Voxelotor under the compassionate program had improvements in multiple clinically important endpoints, including hemoglobin levels, daily pain, hospitalizations for vaso-occlusive crisis (VOC), transfusions, depression and overall well-being, noted the Company.

Voxelotor is currently being investigated in a phase III trial in severe sickle cell disease patients age 12 and older, dubbed HOPE.

Near-term catalyst:

-- The Company expects to report top-line data from Part A of the Phase 3 HOPE Study in the first half of 2018.

3. Apellis Pharmaceuticals Inc. (APLS)

Lost 11.29% to close Tuesday's trading at $12.88.

News: No news

The Company's lead drug candidate is APL-2.

APL-2 has been successfully studied in a phase II clinical trial (FILLY) in patients with geographic atrophy associated with age-related macular degeneration. APL-2 is also under two phase Ib trials in paroxysmal nocturnal hemoglobinuria - one as monotherapy and the other as add-on to Soliris.

The Company debuted on the NASDAQ Global Select Market on November 9, 2017, offering its shares at a price of $14.00 each.

4. OptiNose Inc. (OPTN)

Lost 10.48% to close Tuesday's trading at $17.00.

News: No news

Recent events:

-- On September 18, 2017, the FDA approved the Company's New Drug Application for XHANCE for the treatment of nasal polyps in patients 18 years of age and older.
-- On October 13, 2017, the Company went public on the NASDAQ Global Select Market, offering its shares at a price of $16.00 each.

Upcoming event:

The Company will be making a presentation at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference December 14, 2017, at 9 am ET in New York.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT